Congress expands newborn screening for serious viral infection

What it does

This bill requires hospitals to offer newborn screening for congenital Cytomegalovirus (CMV), a viral infection that can cause hearing loss, developmental delays, and other serious complications in infants. It authorizes federal grants to states to develop screening standards, train healthcare providers, and fund research into better screening methods and treatments, with no mandatory screening—hospitals and states may choose to participate.

Why we flagged it

The bill establishes a voluntary newborn screening program for a serious congenital infection, funded through federal grants to states and research institutions. It is a straightforward public-health measure with no hidden mechanisms or narrow beneficiaries.

What the text implies

• The bill's reliance on state-level implementation and the 2-year timeline for state adoption may create uneven screening availability across states, potentially leaving infants in less-resourced states without access to early detection.
• The authorization of 'such sums as may be necessary' for fiscal years 2025–2026 provides no spending cap; actual appropriations will depend on future congressional action and may be insufficient to fund all states.
• Research funding for vaccine development and in-utero treatments could shift the clinical landscape significantly if successful, potentially reducing the burden of congenital CMV but also creating new questions about access and equity in emerging therapies.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill expands access to early detection of a serious congenital infection that can prevent or reduce disability in newborns, funded through federal grants with no new costs to families. The screening is voluntary for hospitals and states, avoiding coercive mandates, and the research funding may yield better diagnostic tools and treatments.

Who stands to gain

• pharmaceutical companies developing CMV vaccines and antivirals
• diagnostic test manufacturers
• healthcare providers and hospitals administering screening
• research institutions receiving NIH grants

Named in the bill

Health Resources and Services Administration (HRSA), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), Discretionary Advisory Committee on Heritable Disorders in Newborns and Children, State health departments, Hospitals and healthcare entities

Where it stands

12 cosponsors: 10 Democrats, 2 Republicans.

• Sep 17, 2025 — Introduced · Congress.gov: “Introduced in House”
• Sep 17, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 3 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $966,331 in lobbying spend. A filing names 44 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Michael Lawler, the sponsor, reported $2,081,571 in PAC receipts in the 2026 cycle.

• American Speech-language-hearing Association — $680,000 on 2 filings
• American Academy of Otolaryngology-head and Neck Surgery — $286,331 on 1 filing

Lobbying Disclosure Act filings through Jul 17, 2026. A filing shows who paid to lobby on a bill it names, not what changed.